Clin2
NCT07011043Possibly a fitRecruiting

Study of budoprutug for lupus

Systemic Lupus Erythematosus

Treatments studied

Part of Immune system & allergy, Skin clinical trials.

This trial tests an investigational drug called budoprutug for people with active systemic lupus erythematosus (SLE) that has not improved after at least two previous treatments. The goal is to see if it can help control lupus symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
30 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with lupus (SLE) using standard criteria.
  • Your lupus is active, with a score of 8 or more on the SLEDAI test.
  • Your lupus has not responded well to at least two prior treatments, including an immunosuppressant or biologic medication.
  • You do not have active or recent serious infections, or other uncontrolled autoimmune diseases.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07409181Recruiting· Phase 2
Testing an experimental pill for active lupus (SLE)

This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.

Beverly Hills, California
NCT07109986Recruiting· Phase 1
Study of UB-VV410 for active lupus or lupus nephritis

This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.

Nanjing
NCT07515014Recruiting· Phase 2
Testing E6742 in Systemic Lupus Erythematosus

This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.

Bengbu, Anhui
NCT07299422Recruiting· Phase 2
Study of SHR-2173 for people with lupus

This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.

Beijing, Beijing Municipality
NCT07323173Recruiting· Phase 1
Safety study of LBL-047 in healthy adults and lupus patients

This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.

Bengbu, Anhui
NCT07001839Not yet recruiting· Phase 1
Study of QLS4131 for people with active lupus

This trial tests an investigational drug called QLS4131 in people with active systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to see if adding QLS4131 can help control lupus activity better.

Hear when a new Systemic Lupus Erythematosus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.